Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.002 | 0.0202 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0196 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0196 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0051 | 0.1926 | 0.1926 |
Schistosoma mansoni | ap endonuclease | 0.002 | 0.0202 | 0.0202 |
Echinococcus multilocularis | tar DNA binding protein | 0.0196 | 1 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0051 | 0.1926 | 0.1926 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.002 | 0.0202 | 0.5 |
Loa Loa (eye worm) | blistered cuticle protein 3 | 0.0075 | 0.3269 | 0.3269 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.002 | 0.0202 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.002 | 0.0202 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0035 | 0.1034 | 0.1034 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.002 | 0.0202 | 0.0202 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.0035 | 0.1061 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.1317 | 0.1317 |
Trypanosoma brucei | ferric reductase transmembrane protein, putative | 0.0035 | 0.1061 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.002 | 0.0202 | 0.5 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.002 | 0.0202 | 0.0202 |
Schistosoma mansoni | ap endonuclease | 0.002 | 0.0202 | 0.0202 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0051 | 0.1926 | 0.1926 |
Schistosoma mansoni | tar DNA-binding protein | 0.0196 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0196 | 1 | 1 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.002 | 0.0202 | 0.5 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.002 | 0.0202 | 0.0202 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0.0202 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.1926 | 0.1926 |
Brugia malayi | Blistered cuticle protein 3 | 0.0075 | 0.3269 | 0.3269 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.002 | 0.0202 | 0.0202 |
Loa Loa (eye worm) | TAR-binding protein | 0.0196 | 1 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.002 | 0.0202 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0196 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0196 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0196 | 1 | 1 |
Onchocerca volvulus | Dual oxidase homolog | 0.0075 | 0.3269 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0196 | 1 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0.0202 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.002 | 0.0202 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0196 | 1 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0035 | 0.1034 | 0.1034 |
Leishmania major | ferric reductase, putative | 0.0035 | 0.1061 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0196 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0035 | 0.1034 | 0.1034 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.002 | 0.0202 | 0.5 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.0035 | 0.1061 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 6 ug ml-1 | Cytotoxicity against human HCT116 cells | ChEMBL. | 1522422 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 1522422 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.